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Abstract
Background: Aconiti brachypodi Radix (Xue-shang-yi-zhi-hao) has been prescribed to manage chronic pain, arthritis,
and traumatic injuries. Bullatine A, a C20-diterpenoid alkaloid, is one of its principle effective compounds. This study
aimed to investigate the anti-hypersensitivity of bullatine A in a variety of rat pain models and explore its mechanisms
of action.
Methods: Rat neuropathic pain, inflammatory pain, diabetic neuropathic pain, and bone cancer pain models were
used. Dynorphin A and pro-inflammatory cytokines were measured in the spinal cord and cultured primary microglia.
Double immunofluorescence staining of dynorphin A and glial and neuronal cellular markers was also measured in the
spinal cord.
Results: Subcutaneous and intrathecal injection of bullatine A dose-dependently attenuated spinal nerve ligation-,
complete Freud’s adjuvant-, diabetes-, and bone cancer-induced mechanical allodynia and thermal hyperalgesia, with
the efficacies of 45–70 % inhibition, and half-effective doses of 0.9–1.9 mg/kg for subcutaneous injection. However,
bullatine A was not effective in blocking acute nociceptive response in the normal condition. Bullatine A specifically
stimulated dynorphin A expression in microglia in the spinal cord in vivo and cultured primary microglia in vitro; the
stimulatory effects were completely inhibited by the microglial inhibitor minocycline. In contrast, bullatine A did not
have an inhibitory effect on peripheral nerve injury- or lipopolysaccharide-induced pro-inflammatory cytokine
expression. The spinal anti-allodynic effects of bullatine A were entirely blocked by intrathecal injection of minocycline,
the specific dynorphin A antiserum, and the selective k-opioid receptor antagonist.
Conclusions: We, for the first time, demonstrate that bullatine A specifically attenuates pain hypersensitivity, regardless
of the pain models employed. The results also suggest that stimulation of spinal microglial dynorphin A expression
mediates bullatine A anti-nociception in pain hypersensitivity conditions.
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Background
Aconiti brachypodi Radix (Xue-shang-yi-zhi-hao), the dried
roots of Aconitum brachypodum Diels and several other
morphologically similar species (genus Aconitum, family
Ranunculaceae), is listed in the Chinese Pharmacopoeia for
its analgesic and anti-rheumatic properties [1–3]. The
bioactive extracts of A. brachypodi Radix, in the forms of
pills, liniment, patch, and injection, are widely prescribed in
China to manage chronic pain, arthritis, and traumatic injur-
ies. As a principal group of compounds present in
Aconitum, approximately 170 alkaloids have been identified
and fell into four skeletal categories: C18-, C19-, C20- and bis-
diterpenoid alkaloids [3–5]. Bullatine A, a C20-diterpenoid
alkaloid, is one of the major effective and quality control in-
gredients identified from A. brachypodi Radix [6]. The
chemical structures of C18-, C19-, and C20-diterpenoid
alkaloids, as well as bullatine A, are presented in Fig. 1. Un-
like the high toxicity of C18- and C19-diterpenoid alkaloids,
such as aconitine, bulleyaconitine A, and lappaconitine, bul-
latine A exhibits significantly lower toxicity (oral half-lethal
dose: bullatine A 754 mg/kg vs. aconitine 1.8 mg/kg in mice)
[3, 7]. It was reported that systemic administration of bulla-
tine A and the ethanol extract of A. brachypodi Radix in-
cluding bullatine A effectively attenuated pain responses in
the mouse hot-plate, acetic acid, and formalin tests [8].
However, no investigations have been published to date on
the anti-nociceptive effects of bullatine A in pain hypersensi-
tivity models.
The crucial role of spinal microglia has been recognized
with regard to the initiation and development of chronic
pain, including neuropathic pain, inflammatory pain, dia-
betic neuropathic pain, and bone cancer pain [9–13]. Acti-
vated microglia have been implicated in chronic pain
states, leading to the production of pro-inflammatory cy-
tokines, such as tumor necrosis factor-α (TNF-α), inter-
leukin (IL)-6, and IL-1β [13, 14]. The cytokines released
from activated microglia can consequently induce central
sensitization of neurons in the spinal dorsal horn by alter-
ing the excitatory or inhibitory synaptic transmission, con-
tributing to pain facilitation [15]. Li et al. showed that
bullatine A, by selectively antagonizing P2X7 receptors,
inhibited ATP-induced microglial death/apoptosis and
P2X receptor-mediated inflammatory response [16]. On
the other hand, bulleyaconitine A, a C19-diterpenoid alkal-
oid of Aconitum, was recently reported to exhibit potent
anti-nociception through stimulation of the dynorphin A
expression in spinal microglia [17].
In this paper, we aimed to investigate the anti-
hypersensitive effects of bullatine A in a variety of rat
models of pain hypersensitivity, including spinal nerve
ligation-induced neuropathic pain, streptozotocin-induced
diabetic neuropathic pain, complete Freud’s adjuvant
(CFA)-induced inflammatory pain, and bone cancer pain.
We also explored the mechanisms underlying bullatine A
anti-nociception, particularly the involvement of expres-
sions of spinal microglial dynorphin A and pro-
inflammatory cytokines. In addition, guan-fu base A is an
anti-arrhythmic C20-diterpenoid alkaloid [18–20] and has
a similar carbon skeleton structure to bullatine A (Fig. 1).
Its effects on nociception in neuropathy and microglial
dynorphin A expression were also comparatively studied.
Methods
Drugs and reagents
Bullatine A and guan-fu base A were purchased from
the National Institute for the Food and Drug Control
Fig. 1 Chemical structures of C18-, C19-, and C20-diterpenoid alkaloids, bullatine A, and guan-fu base A
Huang et al. Journal of Neuroinflammation  (2016) 13:214 Page 2 of 18
(Beijing, China) with purity not less than 98 % deter-
mined by the manufacturer with high-performance
liquid chromatography (HPLC). The molecular weights
of both compounds were verified in house by a high-
resolution mass spectrum (Waters Corporation, Milford,
MA, USA). Dynorphin A(1–17) (sequence: YGGFLR-
RIRPKLKWDNQ) was synthesized by Dang Gang
Peptides Co. (Hangzhou, China) with purity not less than
98 % determined by the manufacturer. Morphine hydro-
chloride, lidocaine, and minocycline were purchased from
the Northeast Pharmaceuticals Group (Shenyang, China),
the First Chengdu Pharmaceuticals Group (Chengdu,
China), and Yuanye Biotech (Shanghai, China), respect-
ively. 5′-Guanidinonaltrindole (GNTI) and streptozotocin
were purchased from Sigma-Aldrich (St. Louis, MO,
USA), and CTAP (sequence : FCYWRTXT) and naltrin-
dole were purchased from Abcam (Cambridge, UK) and
Tocris (Bristol, UK), respectively. The rabbit polyclonal
antibody-neutralizing dynorphin A was purchased from
Phoenix Pharmaceuticals (Burlingame, CA, USA). Based
on the manufacturer’s information, the antiserum was spe-
cific to dynorphin A (100 %), but not to dynorphin B
(0 %), β-endorphin (0 %), α-neo-endorphin (0 %), or leu-
enkephalin (0 %). Its specificity was also validated by the
antigen absorption test from other laboratories [21, 22].
All the drugs and reagents were dissolved or diluted in
0.9 % normal saline except streptozotocin which was
freshly dissolved in the citrate buffer (pH 4.3).
Experimental animals
Male and female adult (160–250-g body weight) and 1-
day-old neonatal Wistar rats were obtained from the
Shanghai Experimental Animal Institute for Biological
Sciences (Shanghai, China). The adult animals were
housed (three to four per cage) in the Shanghai Jiao Tong
University Experimental Animal Center (Shanghai, China)
at standard room temperature (22 ± 2 °C), under condi-
tions of a 12/12-h reversed light-dark cycle (7:00 a.m.–
7:00 p.m.), and received food and water ad libitum. Adult
rats were accustomed to the laboratory environment for
3–5 days before the experiments. Experimental study
groups (n = 6 in each group) were randomly assigned, and
the researcher was blinded to the behavior tests. The re-
search protocols were approved by the Animal Care and
Welfare Committee of Shanghai Jiao Tong University and
carried out in accordance with the animal care guidelines
of the National Institutes of Health.
Primary cell cultures
Glial cells and neurons were isolated from the cortex and
spinal cord of 1-day-old neonatal rats. The isolated cortex
and spinal cord were minced and then incubated with tryp-
sin. Dissociated cells were suspended in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10 %
(vol/vol) fetal bovine serum (FBS), penicillin (100 U/mL),
and streptomycin (100 μg/mL). For glial cell cultures, cell
suspensions were plated in 75-cm2 tissue culture flasks
(1 × 107 cells/flask) pre-coated with poly-L-lysine and main-
tained at 37 °C in a 5 % carbon dioxide incubator. After cul-
ture for 8 days, microglial cells were prepared as floating
cell suspensions by shaking the flasks at 260 rpm for 2 h.
The aliquots were transferred to new plates, and un-
attached cells were removed by washing with serum-free
DMEM. Harvested microglial cells exhibited a purity
>95 %, as determined by the CD11b (OX42) or Iba-1 im-
munoreactivity. After culture for 11 days, astrocytes were
prepared by shaking the flasks for 2 h followed by incuba-
tion with 10 mL of 0.05 % trypsin-ethylenediamine tetraa-
cetic acid (Invitrogen, Grand Island, NY, USA) in a cell
incubator for 15 min to separate the oligodendrocytes from
the astrocytes. After trypsin neutralization with 10 mL of
the complete DMEM medium, the floating cell suspensions
were discarded. A nearly intact layer of astrocytes in the
bed layer was then trypsinized and subcultured convention-
ally. Prepared astrocytes exhibited a purity >90 %, as deter-
mined by the glial fibrillary acidic protein (GFAP)
immunoreactivity.
For the neuronal culture, cell suspensions were plated
in plates pre-coated with poly-L-lysine (100 μg/mL).
After 4 h of incubation in the DMEM with 10 % FBS,
the medium was changed to the Neurobasal (Invitrogen,
Grand Island, NY, USA) containing B27 supplement and
0.5 mM glutamine for further culture. Experiments were
initiated 5–6 days after plating. Harvested neurons ex-
hibited a purity >85 %, as determined by the NeuN
immunoreactivity.
RNA extraction, reverse transcription, and real-time
quantitative polymerase chain reaction (PCR)
TRIzol reagent (Invitrogen, Grand Island, NY, USA) was
used to isolate total RNA from rat ipsilateral spinal lum-
bar enlargements (L3–L5) and primarily cultured cells
[23]. A sample of 1 μg of total RNA was reversely tran-
scribed using a ReverTra Ace qPCR RT-Kit (Toyobo Co.,
Osaka, Japan). Real-time quantitative PCR was carried out
with a Mastercycler ep realplex (Eppendorf, Germany) using
the Realmaster Mix (SYBR Green I) (Toyobo Co., Osaka,
Japan). The fold change was calculated using the 2−ΔΔCt
method after normalization to gapdh. The primers were as
follows: 5′-CCA AGG TCA TCC ATG ACA AC-3′ (gapdh
forward); 5′-TCA TCC ATG ACA AC-3′ (gapdh reverse)
[24]; 5′-CCT GTC CTT GTG TTC CCT GT-3′ (prodynor-
phin forward); 5′-AGA GGC AGT CAG GGT GAG AA-3′
(prodynorphin reverse) [25]; 5′-CCC CGA CTA TGT GCT
CCT CAC-3′ (TNF-α forward); 5′-AGG GCT CTT GAT
GGC GGA-3′ (TNF-α reverse); 5′-GGA AGG CAG TGT
CAC TCATTG TG-3′ (IL-1β forward); 5′-GGT CCT CAT
CCT GGA AGC TCC-3′ (IL-1β reverse); 5′-GGG ACT
Huang et al. Journal of Neuroinflammation  (2016) 13:214 Page 3 of 18
GAT GTT GTT GAC AGC C-3′ (IL-6 forward); and 5′-
CAT ATG TAA TTA AGC CTC CGA CTT GTG-3′ (IL-6
reverse) [26].
For the ex vivo study, sham and neuropathic rats received
two intrathecal treatments: (1) 10 μl saline + 10 μl saline; (2)
100 μg minocycline + 10 μl saline; (3) 10 μl saline + 10 μg
bullatine A; and (4) 100 μg minocycline + 10 μg bullatine A.
The second treatment was administered 4 h after the first
treatment, and the ipsilateral spinal lumbar enlargements
were obtained 1 h later. The expressions of prodynorphin A,
TNF-α, IL-1β, and IL-6 were measured using the real-time
PCR.
For the in vitro study, cultured primary cells were under
two treatments in the presence and absence of lipopolysac-
charides (LPS, 10 ng): (1) control + control; (2) 60 μM
minocycline + control; (3) control + 10 μM bullatine A; and
(4) 60 μM minocycline + 10 μM bullatine A. The concen-
tration of minocycline was based on the previous references
[26–29]. The second treatment was administered 1 h after
the first treatment, and the microglia were collected 6 h
later. The expressions of prodynorphin A, TNF-α, IL-1β,
and IL-6 were measured using the real-time PCR.
Intrathecal catheterization and injection in rats
An 18-cm polyethylene catheter (PE-10: 0.28-mm inner
diameter and 0.61-mm outer diameter; Clay Adams, Par-
sippany, NJ, USA) with a volume of 13 μL was inserted
into the rat lumbar level of the spinal cord under inhaled
isoflurane anesthesia (4 % for induction and 1 % for
maintenance) run by an anesthesiameter (Ugo Basile
Gas Anesthesia System, Comerio, Italy). Two days after
recovery from anesthesia, the correct positioning of the
catheter in the spinal cord was verified by administering
4 % lidocaine (10 μL followed by 15 μL of saline for
flushing) with a 50-μL microinjector (Shanghai Anting
Microinjector Factory, Shanghai, China). Only rats that
had no motor impairment following insertion of the
intrathecal catheter were considered for the study, and
only rats that developed immediate bilateral paralysis of
the hindlimbs following intrathecal administration of
lidocaine were selected for the study.
Rat model of neuropathic pain
To induce neuropathic pain, the adult male rats were
subjected to spinal nerve ligation as described previously
[23, 30]. Under inhaled isoflurane anesthesia, the left L5
and L6 spinal nerves were isolated and tightly ligated
with 6–0 silk thread. Sham rats were under the same
procedure except for the spinal nerves were not ligated.
After ligation, the wound was sutured and the rats were
allowed to recover. Of the spinal nerve-ligated animals,
only those with marked unilateral allodynia to mechan-
ical stimulation (hindlimb withdrawal thresholds in the
operated side <8 g), and no major impairment were
included in the study. When intrathecal injection was
needed, the intrathecal catheterization was performed in
rats at the same time just before spinal nerve ligation.
Drug testing started on 2–4 weeks after the surgery of
spinal nerve ligation.
Rat model of complete Freud’s adjuvant (CFA)-induced
inflammatory nociception
CFA inflammatory nociception was induced according
to Butler et al. [31] and Fan et al. [26]. Briefly, 100 μL of
CFA (Sigma-Aldrich, MO, USA) was injected into the
tibiotarsal joint of the left hindpaw of each adult male
rat under mild inhaled isoflurane anesthesia. The tibio-
tarsal joint injection of CFA produced immediate and
long-lasting inflammation and pain hypersensitivity. The
rats entered into the behavior tests 2 days after CFA
injection.
Rat model of diabetic neuropathic pain
The adult male rats were fasted for 16 h before receiving
a single intravenous injection of streptozotocin (40 mg/
kg) [24, 32]. High blood sugar levels were observed on
the third day after injection. Mechanical allodynia was
measured by electronic von Frey hairs 4–5 weeks
afterward.
Rat model of bone cancer pain
The rat bone cancer pain model was produced as de-
scribed previously [23, 33]. Adult, female rats were anes-
thetized with intraperitoneal pentobarbital (50 mg/kg).
Incisions were made along the patellar ligament to ex-
pose the head of the left tibia with minimal damage. A
23-gauge needle was inserted at the site of intercondylar
eminence and pierced 7 mm below the knee joint into
the medullary cavity of the tibia. The needle was then re-
moved and attached to a 10-μL microinjection syringe.
Walker 256 carcinoma cells (4 × 105) in 10 μL the phos-
phate buffer solution were slowly injected into the tibia
cavity. The syringe remained for an additional 1 min to
prevent the carcinoma cells from leaking out. The injec-
tion site was then closed with aseptic bone wax, and the
wound was then closed and dusted with penicillin pow-
der. After recovery from the inoculation surgery, rats
were returned to their home cages. The withdrawal
thresholds of contralateral and ipsilateral hindlimbs were
measured by the application of electronic von Frey hairs
2 weeks afterward.
Behavioral assessments of mechanical allodynia
and thermal hyperalgesia in rats
To evaluate mechanical allodynia, the animals were accli-
matized for at least 30 min to the test environment, namely
a plexiglass box on a metal grid. The hindpaw withdrawal
threshold was measured by a 2391 CE Electronic von Frey
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hair (IITC Life Science Inc, Woodland Hill, CA, USA). The
monofilament (with forces ranging from 0.1 to 90 g) was
applied to the foot pad with increasing force until the rats
suddenly withdrew their hindlimbs. The lowest force pro-
ducing a withdrawal response was considered as the thresh-
old. Three repeated measurements were made at intervals
of approximately 3 min, and the three threshold values
were averaged for each hindpaw at each time point.
To assess heat hyperalgesia, rats were put in a plexi-
glass box on an elevated glass surface. Following an
adaption period of at least 30 min, radiant heat source
(at a low density of 45) was applied to the plantar medial
surface of each hindpaw. The hindpaw withdrawal la-
tency was measured by a 390G Plantar Test Analgesia
Meter (IITC Life Science Inc.). To prevent tissue dam-
age, the cutoff was set at 30 s. The paw withdrawal la-
tency was defined as the time from the onset of radiant
heat application to the withdrawal of the hindpaws. Both
hindpaws were tested independently three times with a
5-min interval between the trials. The result was calcu-
lated as the mean of the three repeated measurements.
For the dose response of systemic bullatine A study, two
groups of rats from four different pain models were sub-
cutaneously injected with 1 mL/kg saline or 0.3, 0.7, 2, 7,
and 20 mg/kg of bullatine A sequentially in 1-h intervals
to yield a cumulative dose of approximately 0.3, 1, 3, 10,
and 30 mg/kg. The mechanical or thermal thresholds were
measured 1 h after each injection. For the dose response
of intrathecal bullatine A study, six groups of neuropathic
rats received a single intrathecal injection of saline (10 μL)
and four doses of bullatine A (0.3, 1, 3, 10 and 30 μg). The
withdrawal thresholds to mechanical and thermal stimuli
in both contralateral and ipsilateral hindlimbs were mea-
sured prior to and 0.5, 1, 2, and 4 h after injection.
For the antagonist intervention study, groups of neuro-
pathic rats in each study received two intrathecal injections
of the vehicle (10 μL) + bullatine A (10 μg)/dynorphin A
(1 μg) and the antagonist + bullatine A (10 μg)/dynorphin
A (1 μg). All of the second treatments were administered
0.5 h after the first treatment except minocycline which
was given 4 h after the first injection. The withdrawal
thresholds to mechanical stimuli in both contralateral and
ipsilateral hindlimbs were measured prior to and 0.5, 1, 2
and 4 h after the second injection. The time and dose regi-
mens of the antagonists in the studies were based on the
following references: (1) the microglial inhibitor minocy-
cline (100 μg) [34, 35]; (2) the specific dynorphin A anti-
serum (1:10 dilution) [17]; and (3) the selective μ-opioid
antagonist CTAP (10 μg), k-opioid antagonist GNTI
(50 μg), and σ-opioid antagonist naltrindole (5 μg) [36].
Immunofluorescence staining
Double immunofluorescence labeling of dynorphin A
and microglia, astrocytes, or neurons on spinal cord
sections was undertaken and observed using a TCS SP8
confocal microscope (Leica Microsystems, Wetzlar,
Germany) by modified protocols [24]. Rats were anesthe-
tized by pentobarbital injection (40 mg/kg) and intracardi-
ally perfused with 100 mL normal saline, followed by
60 mL of 4 % paraformaldehyde (w/v) in PBS. Spinal lum-
bar enlargements (L3–L5) were collected and fixed in 4 %
buffered paraformaldehyde for 12 h and placed in 30 % su-
crose solution for 48 h at 4 °C. Tissues were entrapped in
the OCT embedding agent (Leica Microsystems) and cut
into 30-μm-thick frozen sections, which were incubated in
10 % goat serum (v/v) and 0.5 % Triton X-100 (v/v) in
PBS for 1 h, then incubated with the rat dynorphin A anti-
body (1:100; rabbit polyclonal, Phoenix Pharmaceuticals)
and other primary antibodies at 4 °C for 24 h. Spinal neur-
onal and glial cells were identified by the following cellular
markers: Iba-1 (1:100; mouse monoclonal; Millipore,
Darmstadt, Germany) for microglia, GFAP (1:100; mouse
polyclonal; Millipore) for astrocytes, and NeuN (1:60;
mouse polyclonal; Millipore) for neurons. The dynorphin
A was visualized with the Alexa-555-conjugated goat anti-
rabbit secondary antibody (1:200, Invitrogen). Other anti-
bodies were detected with the Alexa-488-conjugated goat
anti-mouse secondary antibody (1:200, Invitrogen).
For quantity measurement of dynorphin A and/or Iba-1/
GFAP/NeuN-immunopositive cell intensity in the spinal
cord, photomicrographs of the medial three fourths of the
superficial dorsal horn (laminas I–V) were captured under
a 10× or 40× magnification. The positively stained surface
area was measured by a researcher blinded to the experi-
mental conditions using a computer-assisted image analysis
program (ImageJ Software, National Institutes of Health)
after low and high thresholds were set to exclude back-
ground fluorescence and include immunofluorescent inten-
sity measurements only from positively stained areas. A co-
localization analysis was performed using ImageJ software
with a co-localization finder to generate images in which
co-localized pixels appeared as white. The same configur-
ation setup was used to measure all surface areas in each
experimental group at the same time. The averaged per-
centage immunolabeled surface area was the fraction of the
positive immunofluorescent surface area of the total mea-
sured picture area from three nonadjacent sections of each
spinal cord. Data were then calculated from six rats of each
group.
Data evaluation and statistical analysis
The percentage of the maximal possible effect (% MPE)
was calculated using the following formula: (post-drug
threshold in ipsilateral hindlimb − baseline threshold in ip-
silateral hindlimb)/(baseline threshold in contralateral
hindlimb − baseline threshold in ipsilateral hindlimb) ×
100 [37]. The % MPE values near 100 indicate normal
mechanical thresholds (i.e., near contralateral thresholds)
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while values near 0 indicate allodynia. For the dose–re-
sponse curve analysis, the parameters, i.e., minimum
effect, maximum effect (Emax), half-effective dose (ED50)
or half-effective concentration (EC50), and Hill coeffi-
cient (n), were calculated by fitting non-linear least-
square curves to the relation Y = a + bx, where x = [D]n/
(ED50
n + [D]n) or [C]n/(EC50
n + [C]n). The value of ED50
or EC50 and b (Emax) were projected by yielding a mini-
mum residual sum of squares of deviations from the
theoretical curve [38]. The data were expressed as
means ± SEM or with 95 % confidence limits, and there
were no missing data. The statistical significance was
evaluated by unpaired and two-tailed Student t tests
and one-way or two-way repeated-measure analysis of
variance (ANOVA) in Prism (version 5.01, GraphPad
Software, Inc., San Diego, CA, USA). The post hoc
Student–Newman–Keuls test was conducted when the
effect of the drug (dose) (for the one-way ANOVA, the
factor was drug [dose]; for the two-way ANOVA, the
factors were drug [dose], time, and their interaction)
was observed to be statistically significant. The prob-
ability values were two-tailed, and the statistical signifi-
cance criterion P value was 0.05.
Results
Systemic bullatine A specifically attenuated pain
hypersensitivity in a variety of pain models
The anti-nociceptive effect of bullatine A was first exam-
ined in the rat model of neuropathic pain. Tight ligation
of peripheral L5/L6 spinal nerves induced marked ipsi-
lateral mechanical allodynia and thermal hyperalgesia.
Two groups of neuropathic rats received subcutaneously
injections of the vehicle (0.9 % saline, 1 mL/kg) and bul-
latine A (3 mg/kg). The paw withdrawal responses to
mechanical and thermal stimuli were measured before
and 0.5, 1, 2, and 4 h after injection. Subcutaneous bulla-
tine A time-dependently alleviated mechanical allodynia
(Fig. 2a) and thermal hyperalgesia (Fig. 2b) in ipsilateral
Fig. 2 Inhibitory effects of bullatine A administered subcutaneously, in a single dose (3 mg/kg) or the cumulative dose range of 0.3 to 30 mg/kg, on
mechanical allodynia and heat hyperalgesia in neuropathic (a–e) and diabetic (f–h) rats. Neuropathic pain was induced by tight ligation of L5/L6
spinal nerves, and diabetic neuropathic pain was induced by intravenous injection of streptozotocin (40 mg/kg). e, h Dose–response analysis of
bullatine A on % maximum possible effect (% MPE) at 1 h after injection was best projected by the non-linear least-squares method. The data are pre-
sented as means ± SEM (n = 6 in each group). Symbol a denotes statistical significance compared with the saline control group (P < 0.05, two-way
ANOVA followed by the post hoc Student–Newman–Keuls tests)
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paws, with the peaks at 1 h and durations of nearly 4 h
(P < 0.05, by two-way ANOVA followed by the post hoc
Student–Newman–Keuls tests). Subcutaneous bullatine
A did not significantly alter normal withdrawal response
to mechanical and heat stimuli in contralateral paws. No
apparent sedation or motor side effects of bullatine A
were observed during the study period. In addition,
cumulative dose–response of bullatine A was conducted in
two groups of neuropathic rats. Animals received repetitive
subcutaneous injection of saline or bullatine A at 1-h inter-
vals. The mechanical or thermal thresholds were measured
before and 1 h after each dose injection. Subcutaneous bul-
latine A dose-dependently alleviated mechanical allodynia
(Fig. 2c) and thermal hyperalgesia (Fig. 2d) in ipsilateral
paws. The dose–response analyses were projected from the
% MPE values from each dose for the blockade of mech-
anical allodynia and heat hyperalgesia. The ED50 values
calculated were 1.9 and 0.7 mg/kg, and the Emax values
were 56.6 and 66.1 % MPE, respectively (Fig. 2e).
Intravenous injection of streptozotocin (40 mg/kg) in
rats produced immediate and permanent high blood
sugar (>16.7 mmol/L) and resulted in stable painful
neuropathy 4–5 weeks later, represented by bilateral
mechanical allodynia [39]. Subcutaneous injection of
bullatine A (3 mg/kg) was effective in attenuation of
mechanical allodynia in a time-dependent manner, with
the peak effect at 1 h after injection (P < 0.05, by two-way
ANOVA followed by the post hoc Student–Newman–
Keuls tests) (Fig. 2f). Cumulative doses (0.3–30 mg/kg) of
subcutaneous bullatine A attenuated mechanical allodynia
in a dose-dependent manner (Fig. 2g), with the ED50 value
of 1.2 mg/kg and Emax value of 65.5 % MPE, which were
projected from the dose–response analyses using % MPE at
1 h after injection calculating from the pre-streptozotocin
paw withdrawal thresholds of 37.9 ± 1.9 g (Fig. 2h).
We further determined the anti-nociceptive effect of
bullatine A in CFA-induced acute inflammatory nocicep-
tion. Two groups of CFA-treated rats received subcutane-
ous injection of the vehicle (0.9 % saline, 1 mL/kg) and
bullatine A (3 mg/kg). Subcutaneous injection of bullatine
A did not significantly alter the paw withdrawal responses
in contralateral paws during the 4-h observation period.
However, bullatine A significantly blocked mechanical
allodynia (Fig. 3a) and thermal hyperalgesia (Fig. 3b) in ip-
silateral paws in a time-dependent manner, with the peak
of 1 h after injection (P < 0.05, by two-way ANOVA
followed by the post hoc Student–Newman–Keuls tests).
In a cumulative dose range of 0.3 to 30 mg/kg, subcutane-
ous injection of bullatine A dose-dependently alleviated
mechanical allodynia (Fig. 3c) and thermal hyperalgesia
(Fig. 3d) in ipsilateral paws. The calculated ED50 values for
the blockade of mechanical allodynia and thermal hyper-
algesia were 1.4 and 0.6 mg/kg, and the Emax values were
50.2 % MPE and 60.2 % MPE, respectively (Fig. 3e).
Tibia implantation of cancer cells produced progres-
sive mechanical allodynia in rats 14 days after surgery.
As shown in Fig. 3f, subcutaneous injection of bullatine
A (3 mg/kg) blocked bone cancer-induced mechanical
allodynia in ipsilateral paws with the peak effect at 1 h
and the duration of almost 4 h (P < 0.05, by two-way
ANOVA followed by the post hoc Student–Newman–
Keuls tests). It did not significantly affect withdrawal
thresholds in contralateral paws. Subcutaneous injection
of bullatine A (0.3 to 30 mg/kg, cumulative doses) dose-
dependently increased withdrawal thresholds in ipsilat-
eral paws (Fig. 3g), with the ED50 value of 0.9 mg/kg and
Emax value of 45.6 % MPE calculated from the % MPE
values at 1 h after injection (Fig. 3h).
Intrathecal bullatine A specifically attenuated neuropathic
pain
In order to test the anti-nociceptive efficacy of bullatine
A in the spinal cord, six groups of neuropathic rats re-
ceived a single intrathecal injection of saline (10 μL) or
bullatine A at different doses (0.3, 1, 3, 10, and 30 μg).
As shown in Fig. 4a, intrathecal bullatine A markedly
suppressed mechanical allodynia in ipsilateral paws in a
dose-dependent manner but did not significantly alter
withdrawal thresholds in contralateral paws. No appar-
ent sedation or motor side effects of bullatine A were
observed during the study period. The anti-allodynic ef-
fect was time-dependent, with a peak effect at 1 h after
injection and a duration of 4 h. Dose–response analysis
showed that the ED50 value was 1.1 μg and Emax value
was 55.5 % MPE, as calculated from the 1 h data after
injection (Fig. 4b). On the contrary, intrathecal injection
of the bullatine A analog guan-fu base A, at the most
tolerable dose of 100 μg, did not show any significant
anti-allodynic effects (Fig. 4c).
Bullatine A upregulated the spinal microglial
prodynorphin expression
To test whether bullatine A affected the spinal gene ex-
pressions of dynorphin A and pro-inflammatory cytokines,
four groups of neuropathic rats received intrathecal injec-
tion of saline (10 μL) or minocycline (100 μg) followed by
a single dose of saline (10 μL) or bullatine A (10 μg) 4 h
afterward. The rats were sacrificed 1 h after the second
treatment, and ipsilateral lumbar enlargements (L3–L5) of
the spinal cord were obtained. The cellular prodynorphin
gene expression relative to gapdh was measured by real-
time quantitative PCR in spinal homogenates. Since we re-
cently reported that the C19-diterpenoid alkaloid
bulleyaconitine-increased dynorphin A level measured by
enzyme-linked immunosorbent assay was in parallel with
the prodynorphin gene expression [17], the prodynorphin
gene expression was only measured in this study. As
shown in Fig. 5a, peripheral nerve injury approximately
Huang et al. Journal of Neuroinflammation  (2016) 13:214 Page 7 of 18
20 days after surgery did not significantly change the basal
prodynorphin gene expression, which was consistent with
our previous results in which spinal nerve injury did not
alter the basal spinal dynorphin A level [17]. Intrathecal
bullatine A significantly increased the prodynorphin ex-
pression by 1.9- and 2.1-fold in the sham and neuropathic
rats, respectively. Intrathecal injection of the microglial in-
hibitor minocycline [40, 41] completely inhibited bullatine
A-increased prodynorphin expression (P < 0.05, by one-
way ANOVA followed by the post hoc Student–New-
man–Keuls tests), although it did not significantly alter
the baseline prodynorphin expression.
The expression of pro-inflammatory cytokines was also
measured in the same rats. Compared to the sham rats,
spinal nerve ligation dramatically increased the spinal ex-
pression of TNF-α, IL-1β, and IL-6 by approximately 8-,
6- and 14-fold, respectively (P < 0.05, by one-way ANOVA
followed by post hoc Student–Newman–Keuls tests). Pre-
treatment with minocycline completely blocked nerve
injury-increased TNF-α (Fig. 5b), IL-1β (Fig. 5c), and IL-6
(Fig. 5d) expression (P < 0.05, by one-way ANOVA
followed by post hoc Student–Newman–Keuls tests). In
contrast, intrathecal administration of bullatine A did not
significantly affect the gene expression of cytokines, in-
cluding TNF-α (Fig. 5b), IL-1β (Fig. 5c), and IL-6 (Fig. 5d),
in either sham or neuropathic rats.
We further determined the effects of bullatine A on
the expression of prodynorphin and pro-inflammatory
cytokines in microglial cells in the presence and absence
of LPS. Cultured primary microglial cells (1 × 106 cells
per well) from the cortex of neonatal rats were treated
with minocycline (60 μM) 1 h prior to LPS (10 ng/mL)
or bullatine A (10 μM) treatment, and microglial cells
were collected 6 h later. Treatment with minocycline at
60 μM for 24 h did not affect microglial viability mea-
sured by the MTT assay (100 % ± 9.5 % vs. 103.8 % ±
6.0 %, n = 5), consistent with the previous report. As
shown in Fig. 6a, LPS (10 ng/mL) did not significantly
Fig. 3 Inhibitory effects of bullatine A administered subcutaneously, in a single dose (3 mg/kg) or the cumulative dose range of 0.3 to 30 mg/kg,
on mechanical allodynia and heat hyperalgesia in complete Freud’s adjuvant (CFA) induced inflammatory pain (a–e) and bone cancer pain (f–h)
rats. The inflammatory model was induced by tibiotarsal joint injection of CFA (100 μL), and the bone cancer pain model was induced by tibia
implantation of Walker 256 carcinoma cells. e, h Dose–response analysis of bullatine A on % maximum possible effect (% MPE) at 1 h after injection
was best projected by the non-linear least-squares method. The data are presented as means ± SEM (n = 6 in each group). Symbol a denotes statistical
significance compared with the saline control group (P < 0.05, two-way ANOVA followed by the post hoc Student–Newman–Keuls tests)
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change the baseline expression of the prodynorphin gene
[29], whereas bullatine A (10 μM) markedly increased
the prodynorphin expression by 2.0- and 2.5-fold in the
absence and presence of LPS, respectively. In agreement
with the in vivo findings in the spinal cord, minocycline
completely inhibited bullatine A-induced increase in the
prodynorphin expression (P < 0.05, by one-way ANOVA
followed by post hoc Student–Newman–Keuls tests),
without affecting the baseline level in the absence and
presence of LPS. However, bullatine A at 10 μM did not
significantly affect the prodynorphin gene expression in
cultured primary astrocytes originated from the cortex
(Fig. 6b) or neurons either from the cortex (Fig. 6b) or
from the spinal cord (relative expression value 1.0 ± 0.1
vs. 0.9 ± 0.3).
In order to compare the stimulatory effect of bullatine A
and guan-fu base A on the prodynorphin gene expression,
cultured primary microglial cells were treated with different
concentrations of bullatine A (1 × 10−6, 3 × 10−5, 1 × 10−5,
3 × 10−5, and 1 × 10−4 M) or of guan-fu base A (1 × 10−6,
3 × 10−5, 1 × 10−5, 3 × 10−5, 1 × 10−4 and 3 × 10−4 M) for 6 h
and the cellular prodynorphin gene was measured by real-
time PCR. Cell viability was not affected under the tested
bullatine A or guan-fu base A. As shown in Fig. 6c, bulla-
tine A increased the prodynorphin gene expression in a
concentration-dependent manner, with an EC50 value of
3.2 μM. In contrast, guan-fu base A up to 300 μM did not
significantly affect the expression of prodynorphin.
Treatment with LPS produced an extraordinary in-
creases (26-, 30-, and 35-fold) in the expressions of TNF-
α, IL-1β, and IL-6 mRNA, respectively (P < 0.05, by one-
way ANOVA followed by post hoc Student–Newman–
Keuls tests). As shown in Fig. 6d–f, minocycline com-
pletely blocked LPS-induced overexpression of TNF-α, IL-
1β, and IL-6 (P < 0.05, by one-way ANOVA followed by
the post hoc Student–Newman–Keuls tests), although it
did not affect their baseline expressions. In contrast, the
treatment with bullatine A did not significantly inhibit the
gene expression of those pro-inflammatory cytokines in
the presence or absence of LPS stimulation.
Bullatine A induced dynorphin A upregulation in spinal
microglia in neuropathic rats
We examined the differential distribution of dynorphin
A in the spinal cord of neuropathic rats treated with
intrathecal saline (10 μL) or bullatine A (10 μg). In con-
trol rats, the dynorphin A immunofluorescence staining
was widely expressed throughout the white and gray
matter of the spinal cord, particularly in laminae I–V of
the dorsal horn and dorsolateral to the central canal
(Fig. 7a), in agreement with previous immunohistochem-
ical staining in naïve and polyarthritic rats [42]. After
1 h treatment of bullatine A, dynorphin A staining was
much more intense in the ipsilateral dorsal horn
(Fig. 7b). Upregulation of dynorphin A expression in the
ipsilateral dorsal horn I–V laminae was quantified using
Fig. 4 Effects of bullatine A (a, b) and guan-fu base A (c) administered intrathecally on mechanical allodynia in neuropathic rats. Neuropathic pain
was induced by tight ligation of L5/L6 spinal nerves. b Dose–response analysis of bullatine A on % maximum possible effect (% MPE) at 1 h after
injection was best projected by the non-linear least-squares method. The data are presented as means ± SEM (n = 6 in each group)
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the computer-assisted image quantification program.
Compared to saline-treated rats, bullatine A significantly
increased the averaged percentage immunolabeled sur-
face area by 104 % (P < 0.05, unpaired and two-tailed
Student t test) (Fig. 7c). Immunofluorescence was also
stained with the microglial marker Iba-1, astrocytic
marker GFAP, and neuronal marker NeuN. After treat-
ing with bullatine A, ipsilateral (laminae I–V) expres-
sions of microglial (Fig. 7d–f ), astrocytic (Fig. 7g–i), and
neuronal (Fig. 7j–l) markers were not significantly chan-
ged, compared to the saline-treated rats.
Dynorphin A has been reported to be localized and se-
creted in neurons, astrocytes, and microglia [17, 43, 44].
To identify cell types that specifically promote expression
of dynorphin A in the spinal dorsal horn after bullatine A
treatment, we performed double immunofluorescence la-
beling of dynorphin A with microglial, astrocytic, and
neuronal cellular markers. As shown in Fig. 8a–d, dynor-
phin A immunofluorescence was co-labeled with Iba-1 on
microglia in the I–V laminae of the dorsal horn in saline-
treated rats. Double immunofluorescence of dynorphin A
with Iba-1 was significantly upregulated after treatment of
bullatine A by 3.4-fold, as measured using the computer-
assisted image analysis program (P < 0.05, unpaired and
two-tailed Student t test) (Fig. 8e). Dynorphin A was also
co-labeled with GFAP on astrocytes and NeuN on neu-
rons in the spinal dorsal horn. However, there was no sig-
nificant difference in co-immunofluorescence staining of
dynorphin A and GFAP (Fig. 8f–j) or NeuN (Fig. 8k–o)
between saline- and bullatine A-treated rats.
Intrathecal the microglial inhibitor, dynorphin A
antiserum, and k-opioid receptor antagonist suppressed
bullatine A-induced anti-nociception
In order to test whether the spinal microglial dynorphin
A expression was causally associated with bullatine A
anti-nociception, the microglial inhibitor minocycline,
the specific dynorphin A antiserum [17], and antagonists
of the opioid receptor subtypes were applied. Two
groups of neuropathic rats were first given an intrathecal
injection of 10 μL of saline or 100 μg of minocycline,
followed by a second intrathecal injection of 10 μg of
bullatine A 4 h later. Hindpaw withdrawal thresholds to
the mechanical stimulus were measured before and 0.5,
1, 2, and 4 h after the second administration. The effects
of minocycline in neuropathic pain are complex when
different treatment regimens are applied. It is generally
accepted that treatment with minocycline may not be
anti-nociceptive in established neuropathy, although its
preemptive treatment prevented the induction and/or
Fig. 5 Effects of the intrathecal injection of bullatine A on the gene expression of prodynorphin (a) and pro-inflammatory cytokines, including
tumor necrosis factor (TNF)-α (b), interleukin (IL)-1β (c), and IL-6 (d) in sham rats and neuropathic rats. Peripheral neuropathy was induced by the tight ligation
of L5/L6 spinal nerves, and sham rats were under the same procedure except for the spinal nerves which were not ligated. The ipsilateral spinal lumbar
enlargements were obtained 1 h after the intrathecal injection of saline or bullatine A (10 μg). The expression of prodynorphin and pro-inflammatory
cytokines was measured by real-time quantitative PCR relative to the gapdh gene. The data are presented as means ± SEM (n= 6 in each group). Symbols a
and b denote statistical difference compared with the saline plus saline group and saline plus bullatine A group in sham or neuropathic rats (P< 0.05,
one-way ANOVA followed by the post hoc Student–Newman–Keuls test)
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early development of neuropathic pain [17, 24, 26, 27,
40, 45–48]. As shown in Fig. 9a, intrathecal injection of
bullatine A produced time-dependent anti-allodynic ef-
fects. Minocycline did not significantly alter the basal
withdrawal response in either paws but entirely inhibited
the anti-allodynic effects exerted by bullatine A in ipsi-
lateral paws (P < 0.05, by two-way ANOVA followed by
the post hoc Student–Newman–Keuls tests).
Similarly, two groups of neuropathic rats received
intrathecal injection of 10 μL of blank rabbit serum or
10 μL of the dynorphin A antiserum (1:10 dilution).
Each rat received a second intrathecal injection of 10 μg
of bullatine A 0.5 h later. The paw withdrawal responses
to the mechanical stimulus were measured. The time
and dose regimen of the dynorphin A antiserum was
based on the previous publications [17]. Intrathecal in-
jection of bullatine A produced time-dependent anti-
allodynia in the ipsilateral paws. The dynorphin A anti-
serum entirely prevented bullatine A from suppressing
mechanical allodynia (P < 0.05, by two-way ANOVA
followed by the post hoc Student–Newman–Keuls tests),
although it did not significantly alter the basal with-
drawal response in either paws (Fig. 9b).
As dynorphin A has variously been reported to inhibit
[49, 50] or facilitate pain [51, 52], the effect of dynorphin
A on nociception was tested in our conditions. Three
groups of neuropathic rats received intrathecal injection
of saline (10 μL) and two non-paralytic doses (1 and
10 μg) of the synthetic dynorphin A. Intrathecal admin-
istration of dynorphin A(1–17) dose-dependently sup-
pressed mechanical allodynia in ipsilateral paws, with
the peak effect (48.8 and 60.5 % MPE) at 1 h and a dur-
ation of 4 h (P < 0.05, by two-way ANOVA followed by
the post hoc Student–Newman–Keuls tests) (Fig. 9c).
In physiological conditions, dynorphin A modulates
anti-nociceptive response primarily through the activa-
tion of the k-opioid receptor located on neurons in the
descending inhibitory system, although it has some affin-
ity for μ- and δ-opioid receptors [53, 54]. To confirm
which subtype of opioid receptors was responsible for
dynorphin A anti-nociception, we tested the possible
blockade effects of the selective μ-opioid receptor antag-
onist CTAP [55], k-opioid receptor antagonist 5′-guani-
dinonaltrindole (GNTI) [56], and δ-opioid receptor
antagonist naltrindole [57] on dynorphin A-exerted anti-
allodynia. It is noted that we selected GNTI instead of
the traditionally used nor-binaltorphimine as the latter
was recently reported to be an inverse agonist of the k-
opioid receptor [58, 59]. Four groups of neuropathic rats
received the following pairs of intrathecal injections:
Fig. 6 Effects of bullatine A and guan-fu base A on gene expressions of prodynorphin (a, b, c) and the tumor necrosis factor (TNF)-α (d), interleukin
(IL)-1β (e), and IL-6 (f) in primary cultures of microglia, astrocytes, and neurons in the presence and absence of lipopolysaccharides (LPS). The primary
microglial cells, astrocytes, and neurons were derived from the cortex of neonatal rats. Minocycline (60 μM) was treated 1 h before LPS (10 ng/mL) and
bullatine A (10 μM) treatment. The cultured cells were collected 6 h later, and the expression of prodynorphin and pro-inflammatory cytokines was
determined by real-time quantitative PCR relative to the gene of gapdh. The data are presented as means ± SEM (n = 3–5 in each treatment, with three
independent repeats). Symbols a and b denote statistical difference compared with the control group and bullatine A group in the presence and
absence of LPS (P < 0.05, one-way ANOVA followed by the post hoc Student–Newman–Keuls test)
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saline (10 μL) + dynorphin A(1–17) (1 μg), GNTI (50 μg) +
dynorphin A(1–17) (1 μg), CTAP (10 μg) + dynorphin
A(1–17) (1 μg), and naltrindole (5 μg) + dynorphin A(1–17)
(1 μg). The second treatment occurred 0.5 h after the first
injection, and the paw withdrawal responses to the mech-
anical stimulus were measured before and 0.5, 1, 2, and 4 h
thereafter. As shown in Fig. 9d, intrathecal injection of
GNTI, but not CTAP or naltrindole, totally prevented the
anti-allodynic effect of dynorphin A (P < 0.05, by two-way
ANOVA followed by the post hoc Student–Newman–
Keuls tests), although it was ineffective in altering the basal
withdrawal thresholds in both paws.
Lastly, the above selective opioid receptor antagonist
was employed to determine which subtype of opioid re-
ceptors participated in bullatine A anti-nociception. Four
groups of neuropathic rats received intrathecal injections
of saline (10 μL), GNTI (50 μg), CTAP (10 μg), and nal-
trindole (5 μg) before being intrathecally given bullatine
A (10 μg). The second administration occurred 0.5 h
after the first injection, and the paw withdrawal re-
sponses to mechanical stimulus were measured. As
shown in Fig. 9e, intrathecal injection of bullatine A in-
duced time-dependent anti-allodynia in ipsilateral paws.
In contrast to the negative effects of intrathecal CTAP
Fig. 7 Stimulatory effects of intrathecal injection of bullatine A on dynorphin A immunofluorescence staining in the ipsilateral spinal dorsal horn
of neuropathic rats. Peripheral neuropathy was induced by unilateral L5–L6 spinal nerve ligation for 2 weeks, and frozen sections were obtained
1 h after intrathecal saline (10 μL) or bullatine A (10 μg) treatment. Immunofluorescence was labeled with the dynorphin A antibody (a, b),
microglial marker Iba-1 (d, e), astrocytic marker GFAP (g, h), and neuronal marker NeuN (j, k). Photomicrographs were taken from the ipsilateral
spinal cords. The immunolabeled surface areas for dynorphin A (c), Iba-1 (f), GFAP (i), and NeuN (l) were quantified from the spinal dorsal horn (laminae
I–V) using the ImageJ computer program. Data are expressed as mean ± SEM (n = 6 in each group). Symbol a denotes statistical difference from the
spinal cord group treated with saline (P < 0.05 by unpaired and two-tailed Student t test). Scale bars: 250 μm
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and naltrindole on bullatine A anti-allodynia, intrathecal
injection of GNTI completely inhibited the anti-
allodynic effects of bullatine A (P < 0.05, by two-way
ANOVA followed by the post hoc Student–Newman–
Keuls tests), without affecting the baseline withdrawal
response in both paws.
Discussion
Our study, for the first time, demonstrated that bullatine
A was effective in blocking spinal nerve ligation- and
CFA-induced mechanical allodynia and thermal hyper-
algesia and diabetic- and bone cancer-induced mechan-
ical allodynia with efficacies of 45–70 % MPE and ED50
values of 0.9–1.9 mg/kg by subcutaneous injection. It is
worth noting that bullatine A does not show any inhibi-
tory effects of nociceptive responses stimulated by
mechanical or thermal stimuli in normal physiological
conditions, suggesting that bullatine A was rather anti-
hypersensitive than anti-noxious. Our results indicate
that bullatine A is effective in the blockade of pain
hypersensitivity, independent of pain models employed,
and provide the pharmacological evidence to support its
potential use for the treatment of chronic pain.
Emerging evidence indicates that spinal microglia acti-
vation and microglia-derived pro-inflammatory cytokines,
such as IL-1β, IL-6, and TNF-α, play a crucial role in the
pathogenesis of neuropathic pain and other pathological
conditions [60, 61]. As expected, we observed that LPS
and spinal nerve injury dramatically increased expressions
of TNF-α, IL-1β, and IL-6 in cultured primary microglial
cells by 26- to 35-fold and in the spinal cord by 6- to 14-
fold, which were completely blocked by the microglial in-
hibitor minocycline. Minocycline is a broad-spectrum
antimicrobial tetracycline derivative and is generally con-
sidered to be a specific inhibitor of microglia (but not as-
trocytes [62, 63] or oligodendroglial progenitors [64]),
although it was reported to have some direct biological ef-
fects in neurons [65, 66]. Minocycline has been extensively
used to study the role of microglia in experimental models
of brain ischemia [67], traumatic brain injury [68], and
peripheral nerve injury-induced neuropathy [17, 24, 26,
27, 34, 40, 45]. In contrast, bullatine A (1–50 μM) was
Fig. 8 Specific stimulatory effects of intrathecal injection of bullatine A on dynorphin A expression in microglia in the spinal cord using double
immunofluorescence staining technique. Peripheral neuropathy was induced by unilateral L5–L6 spinal nerve ligation for 2 weeks, and frozen
sections were obtained from the spinal lumbar enlargements 1 h after intrathecal saline (10 μL) or bullatine A (10 μg) injection. The double
fluorescence immunostaining was labeled dynorphin A with the microglial marker Iba-1 (a–d), astrocytic marker GFAP (f–i), and neuronal marker
neuronal nuclei NeuN (k–n). Photomicrographs were taken from the ipsilateral spinal cords. Arrows indicate double-labeling of dynorphin A with
cellular biomarkers. The immunolabeled surface areas for double dynorphin A/Iba-1 (e), dynorphin A/GFAP (j), and dynorphin A/NeuN (o) were quantified
in the spinal dorsal horn (laminae I–V) using ImageJ computer program. Data are expressed as mean ± SEM (n= 6 in each group). Symbol a denotes
statistical difference compared to the saline control group (P< 0.05 by unpaired and two-tailed Student t test). Scale bars: a, b, f, g, k, and l, 250 μm; c, d, h,
i, m, and n, 50 μm
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recently reported to decrease ATP-induced overexpres-
sion of IL-1β, IL-6, and inducible nitric oxide synthase in
mouse BV-2 microglial cells [16]. However, our data do
not support the observation either in vitro or in vivo, as
bullatine A at 10 μM or 10 μg did not inhibit LPS- or
spinal nerve injury-induced overexpression of the pro-
inflammatory cytokines in either cultured microglial cells
or the spinal cord.
Instead, we revealed that the anti-hypersensitivity of
bullatine A was produced by the stimulation of dynorphin
A expression in spinal microglia. Dynorphin A is an en-
dogenous opioid neurotransmitter produced in various re-
gions of the brain, including the hypothalamus, the
striatum, the hippocampus, and the spinal cord [69–71].
The localization and secretion of dynorphin A have been
observed in neurons [72, 73], astrocytes [43], and micro-
glia [17]. The effects of dynorphin A on nociception are
bimodal depending on physiological vs. pathological con-
ditions, low vs. high concentrations, and time courses dur-
ing the development of pain hypersensitivity [17]. At low
doses, dynorphin A produces analgesia primarily through
activation of k-opioid receptors located on the neurons in
the descending inhibitory system [50, 53, 54, 74], while at
high concentrations it may induce allodynia and paralysis
through the activation of neuronal and microglial N-me-
thyl-D-aspartic acid (NMDA) receptors [50, 75–77]. The
involvement of spinal microglial-expressed dynorphin A
in bullatine A anti-hypersensitivity is supported by the
following findings. First, bullatine A stimulated prodynor-
phin expression in the primary culture of microglia (but
not of neurons or astrocytes) and the spinal cord and pro-
duced anti-nociception, which were completely blocked
by the microglial inhibitor minocycline. In addition,
double immunofluorescence staining technology revealed
that intrathecal bullatine A-stimulated dynorphin A pro-
tein in the ipsilateral spinal dorsal horn was specifically
co-localized with microglia (but not neurons or astro-
cytes). Moreover, the specific anti-dynorphin A serum,
which has been found to block the anti-allodynic effects of
bulleyaconitine A in neuropathic pain [17], entirely elimi-
nated bullatine A anti-hypersensitivity. Furthermore, the
highly selective k-opioid receptor antagonist GNTI at the
dose to block the anti-nociceptive effect of the synthetic
dynorphin A completely inhibited the anti-hypersensitive
effects of bullatine A in neuropathy. In contrast, the μ-
opioid receptor antagonist CTAP or δ-opioid receptor an-
tagonist naltrindole was not effective in blocking bullatine
A anti-nociception. These results indicate that bullatine A
exerts anti-hypersensitivity by specifically stimulating
spinal microglia to express and secrete dynorphin A,
which then acts on the k-opioid receptors located on the
post-microglial synaptic neurons.
We have also recently reported that the C19-diterpen-
oid alkaloids aconitine and bulleyaconitine A produced
anti-hypersensitivity entirely via stimulation of spinal
microglial dynorphin A expression and secretion which
Fig. 9 Blockade effects of intrathecal injection of the microglial inhibitor minocycline (a), specific dynorphin A antiserum (b), and selective k-opioid
receptor antagonist GNTI (c–e) on bullatine A- and dynorphin A-induced anti-allodynia in neuropathic rats. Neuropathic pain was induced by tight
ligation of L5/L6 spinal nerves. Minocycline, the antiserum, and opioid receptor antagonists were injected intrathecally 4 and 0.5 h before intrathecal
treatment with bullatine A. The data are presented as means ± SEM (n= 6 in each group). Symbols a and b denote statistical significance compared with the
saline control group and bullatine A or dynorphin A group (P< 0.05, two-way ANOVA followed by the post hoc Student–Newman–Keuls tests)
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were not dependent on the interaction with neuronal
sodium channels, and their anti-hypersensitivity was
separated from the neurotoxicity [17]. Taken together,
our results indicate that both C19- and C20-diterpenoid
alkaloids exhibit dynorphin A expression properties, re-
gardless of their different carbon skeletal structures.
However, although the anti-nociceptive efficacy was
nearly the same for both bulleyaconitine A and aconit-
ine, the anti-allodynic potency of bullatine A is nearly
10–32-fold less that of bulleyaconitine A in spinal nerve
ligation-induced neuropathic rats (ED50: 59.5 μg/kg vs.
1.9 mg/kg for subcutaneous injection and 111.3 ng vs.
1.1 μg for intrathecal injection) [17]. In addition, the po-
tency of bullatine A (EC50 3.2 μM) to stimulate dynor-
phin A expression in microglia is around 76-fold less
than that of bulleyaconitine A (EC50 41.9 nM) [17]. The
potencies of anti-hypersensitivity and dynorphin A ex-
pression stimulation between bullatine A and bulleyaco-
nitine A are well positively correlated, which further
supports our note that stimulation of dynorphin A ex-
pression in spinal microglia entirely mediates the anti-
hypersensitivity of Aconitum and its diterpenoid alka-
loids. The findings have made a conceptual advance-
ment, as it was generally accepted that the interaction of
Aconitum and its alkaloids with neuronal sodium chan-
nels were responsible for their analgesia and toxicity [4,
5]. Furthermore, it has been reported that glucagon-like
peptide 1 receptor (GLP-1) receptor agonism-induced
anti-nociception in pain hypersensitivity through spinal
microglial expression of β-endorphin [24, 26]. Our find-
ings of bullatine A and bulleyaconitine A further highlight
that spinal microglia exert an anti-nociceptive role, in
addition to their known pro-nociceptive functions [9–13].
However, it is worthy to note that activation of microglia
may not be required for bullatine A and bulleyaconitine A
to induce dynorphin A expression, as both of them stimu-
lated dynorphin A expression by similar degrees in the ip-
silateral spinal cord from both sham rats and established
neuropathic rats [17] and as bullatine A induced dynor-
phin A expression in the primary culture of microglia with
and without LPS challenge.
Mitogen-activated protein kinases (MAPKs) are a fam-
ily of evolutionally conserved molecules. After being ac-
tivated by phosphorylation, they play a critical role in
cell signaling, particularly in relation to microglial activa-
tion [13, 45, 78]. MAPKs include p38, extracellular
signal-regulated kinase (ERK1/2) and c-Jun N-terminal
kinase (JNK) [79–81]. Minocycline is likely a non-
selective inhibitor of MAPKs, as it has been found to
inhibit activation of all of three MAPK subtypes [34, 35,
82–86]. We recently discovered that bulleyaconitine A
significantly induced cyclic AMP production and activa-
tion of cAMP-dependent protein kinase A (PKA); subse-
quently, PKA specifically regulated the activity of p38
(but not ERK1/2 or JNK) MAPK and its translocation to
the nucleus and then phosphorylated the transcription
factor cyclic AMP-response element binding protein
(CREB), leading to increased prodynorphin expression
and anti-nociception (Li et al., unpublished data, 2016).
Given that minocycline completely blocked bulleyaconi-
tine A- and bullatine A-induced spinal microglial dynor-
phin A expression and anti-nociception, and that both
bullatine A and bulleyaconitine A are diterpenoid alka-
loids and originated from the genus Aconitum, we
speculate that bullatine A shares the same mechanism
with bulleyaconitine A, by which bullatine A stimulates
dynorphin A expression by activation of the microglial
cyclic AMP/PKA/p38 MAPK/CREB signaling pathway.
The structure-activity relationships of C18- and C19-di-
terpenoid alkaloids of Aconitum have been extensively
studied [87]. The C8-acetyl and C14-benzoyl groups were
found to be essential for aconitines to stimulate spinal
microglial dynorphin A expression and subsequent anti-
hypersensitivity, while hydroxylation at C3 and C15 was
also helpful for the actions [17]. In contrast, little infor-
mation has been reported about the structure-activity re-
lationship for C20-diterpenoid alkaloids to produce anti-
nociception. There are seven types of C20-diterpenoid al-
kaloids in nature and five types exist in the Aconitum
species. Bullatine A belongs to the denudatine-type (six-
membered ring and a chemical bond between C-20 and
C-7), and guan-fu base A belongs to the hetisine-type
(the most complicated structure in C20-diterpenoid alka-
loids with a seven-membered ring and a link between N
and C-6), with the significant difference in which the hy-
droxyl group exists in C15 only in bullatine A [3, 88].
The biogenetic relationship studies between C20- and
C19-diterpenoid alkaloids revealed that the bio-
transformation of denudatine-type (but not hetisine-
type) diterpenoid alkaloids is one of the major pathways
to form aconitines, which was specifically regulated by
the C15-hydroxyl group [3]. Our study demonstrated
that the treatment with guan-fu base A up to 300 μM
did not stimulate dynorphin A gene expression in cul-
tured microglia and intrathecal guan-fu base A up to
100 μg did produce anti-nociception in neuropathy,
whereas bullatine A was markedly positive in the param-
eters with high EC50 of 3.2 μM and ED50 of 1.1 μg. The
differential activities suggest that the C15-hydroxyl group
may be required for C20-diterpenoid alkaloids to express
dynorphin A and subsequently anti-nociception.
Conclusions
Systemic and intrathecal injection of bullatine A specif-
ically and dose-dependently inhibits pain hypersensitivity
in a variety of rat models of pain, including neuropathic
pain, bone cancer pain, inflammatory pain, and diabetic
neuropathic pain. Bullatine A stimulates dynorphin A
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expression in the spinal cord and cultured primary
microglia in a minocycline-sensitive manner. The spinal
anti-allodynic effects of bullatine A are entirely blocked
by minocycline, the specific dynorphin A antiserum, and
the selective k-opioid receptor antagonist, indicating that
bullatine A anti-nociception is entirely mediated by the
stimulation of spinal microglial dynorphin A expression.
Our results suggest that both C19- and C20-diterpenoid
alkaloids stimulate dynorphin A expression, regardless of
their different carbon skeletal structures and further
highlight that spinal microglia exert an anti-nociceptive
role in addition to their known pro-nociception.
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